The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

Viking Therapeutics (VKTX) shares crashed nearly 29% in today’s trade after the company’s much-anticipated weight-loss pill ...

Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) ...

Viking Therapeutics (VKTX) stock dove on Tuesday following the release of data from a Phase 2 clinical trial of VK2735. This is the pharmaceutical company’s dual agonist of the glucagon-like peptide 1 ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

Viking Therapeutics stock plunges 37% as trial data sparks concerns over dropout rates and side effects despite weight loss ...

Viking Therapeutics said Tuesday its experimental weight-loss pill helped patients lose 12.2% of their body weight in a ...

Viking Therapeutics reported a large number of patients dropped out of a study of its experimental weight-loss pill.

Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity ...